Lixisenatide treatment improves glycaemic control in Asian patients with type 2 diabetes mellitus inadequately controlled on metformin with or without sulfonylurea: a randomized, double‐blind, placebo‐controlled, 24‐week trial (GetGoal‐M‐Asia)
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Background: This study assessed the efficacy and safety of the once‐daily glucagon‐like peptide‐1 receptor agonist, lixisenatide, in Asian patients with type 2 diabetes mellitus inadequately controlled on metformin ± sulfonylurea. Methods: In this 24‐week, double‐blind, placebo‐controlled, multinational study, patients were randomized to lixisenatide 20 µg once daily or placebo. The primary endpoint was absolute change in glycated haemoglobin (HbA 1c) from baseline to week 24. Results: A total of 391 patients were randomized. Lixisenatide significantly reduced HbA 1c levels compared with placebo (LS mean difference: −0.36%, p = 0.0004). A significantly higher proportion of lixisenatide‐treated patients achieved HbA 1c targets of <7% (p = 0.003) and ≤6.5% (p = 0.001) versus placebo. Lixisenatide was associated with a statistically significant reduction in 2‐h postprandial plasma glucose after a standardized breakfast versus placebo (LS mean difference: −4.28 mmol/L, p < 0.0001) and a significant reduction in fasting plasma glucose (p = 0.0109). There was no difference in weight loss versus placebo, with a modest reduction in body weight reported for both groups (lixisenatide: −1.50 kg, placebo: −1.24 kg; p = 0.296). The incidence of treatment‐emergent adverse events (TEAEs) was 64.3% with lixisenatide versus 47.4% with placebo, with serious TEAEs reported in 1.5% versus 2.1% of patients, respectively. The most common TEAE in the lixisenatide group was nausea (16.3% vs 2.6% with placebo). The incidence of symptomatic hypoglycaemia was 5.6% with lixisenatide treatment and 2.6% with placebo (p = 0.1321), with no severe symptomatic hypoglycaemia events reported. Conclusions: In Asian patients with type 2 diabetes mellitus insufficiently controlled on metformin ± sulfonylurea, lixisenatide significantly improved glycaemic control and was well tolerated during the 24‐week study. © 2014 The Authors. Diabetes/Metabolism Research and Reviews published by John Wiley & Sons, Ltd.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetologia · doi:10.1007/s00125-012-2534-0 · Cited by 3,919
Diabetes in Asia: Epidemiology, Risk Factors, and Pathophysiology
Chan, J. C. N., Malik, V., Jia, W., Kadowaki, T., Yajnik, C. S., Yoon, K.-H., & Hu, F. B. (2009) · JAMA · doi:10.1001/jama.2009.726 · Cited by 1,997
Hu, F. B. (2011) · Diabetes Care · doi:10.2337/dc11-0442 · Cited by 1,954 · cited 1×
“population [2], with substantial rises expected over coming”
BackgroundWhite rice consumption and risk of type 2 diabetes: meta-analysis and systematic review
Hu, E. A., Pan, A., Malik, V., & Sun, Q. (2012) · BMJ · doi:10.1136/bmj.e1454 · Cited by 631 · cited 1×
“In addition, the high consumption of white rice associated with the Asian diet may play a role [7].”
BackgroundCavalot, F., Pagliarino, A., Valle, M., Di Martino, L., Bonomo, K., Massucco, P., Anfossi, G., & Trovati, M. (2011) · Diabetes Care · doi:10.2337/dc10-2414 · Cited by 322 · cited 1×
“PPG has also been shown to be superior to FPG at predicting cardiovascular disease and all-cause mortality [31].”
BackgroundRiddle, M. C., Aronson, R., Home, P., Marre, M., Niemoeller, E., Miossec, P., Ping, L., Ye, J., & Rosenstock, J. (2013) · Diabetes Care · doi:10.2337/dc12-2454 · Cited by 288 · cited 2×
“Lixisenatide has also previously been reported to have a beneficial effect on body weight [24,25,27,39].”
Self-citationRosenstock, J., Raccah, D., Korányi, L., Maffei, L., Boka, G., Miossec, P., & Gerich, J. E. (2013) · Diabetes Care · doi:10.2337/dc12-2709 · Cited by 253
Efficacy and Safety of the Once-Daily GLP-1 Receptor Agonist Lixisenatide in Monotherapy
Fonseca, V. A., Alvarado-Ruiz, R., Raccah, D., Boka, G., Miossec, P., Gerich, J. E., & on behalf of the EFC6018 GetGoal-Mono Study Investigators (2012) · Diabetes Care · doi:10.2337/dc11-1935 · Cited by 218
Ahrén, B., Leguizamo Dimas, A., Miossec, P., Saubadu, S., & Aronson, R. (2013) · Diabetes Care · doi:10.2337/dc12-2006 · Cited by 172 · cited 1×
“6% with placebo) [21] or GetGoal-S (25.”
Bolli, G. B., Munteanu, M., Dotsenko, S., Niemoeller, E., Boka, G., Wu, Y., & Hanefeld, M. (2014) · Diabetic Medicine · doi:10.1111/dme.12328 · Cited by 144
Self-citationMechanisms and clinical efficacy of lixisenatide for the management of type 2 diabetes
Horowitz, M., Rayner, C. K., & Jones, K. L. (2013) · Advances in Therapy · doi:10.1007/s12325-013-0009-4 · Cited by 58
Exenatide once weekly for the treatment of type 2 diabetes
Malone, J., Trautmann, M., Wilhelm, K., Taylor, K., & Kendall, D. M. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780902766802 · Cited by 55
Cited by
Standards of medical care for type 2 diabetes in China 2019
Jia, W., Weng, J., Zhu, D., Ji, L., Lu, J., Zhou, Z., Zou, D., Guo, L., Ji, Q., Chen, L., et al. (2019) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3158 · Cited by 700
Self-citationPharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus
Tahrani, A. A., Barnett, A. H., & Bailey, C. J. (2016) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.86 · Cited by 398
Recent updates on GLP-1 agonists: Current advancements & challenges
Sharma, D., Verma, S., Vaidya, S., Kalia, K., & Tiwari, V. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.08.088 · Cited by 265
Xie, Z., Hu, J., Gu, H., Li, M., & Chen, J. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1244432 · Cited by 47
“Stata software was used to perform sensitivity analyses for the primary outcome indicator (HbA1c reduction) after excluding 10 high-risk studies (5, 8, 10, 12, 16, 19, 20, 25, 32, 33) according to results 3.”
MethodLixisenatide in type 2 diabetes: latest evidence and clinical usefulness
Anderson, S. L., & Trujillo, J. M. (2016) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622315609312 · Cited by 36
Metadata
- Authors
- Yu Pan, C., Han, P., Liu, X., Yan, S., Feng, P., Zhou, Z., Lv, X., Tian, H., Jin Kui, Y., Su, B., Shang, S., & Niemoeller, E.
- Venue
- Diabetes/Metabolism Research and Reviews
- Publisher
- Wiley
- Published
- 2014-11
- Volume
- 30
- Issue
- 8
- Pages
- 726-735
- ISSN
- 1520-7552 (ISSN-L)
- 1520-7560
- OpenAlex
- W1482710124
- Cited by
- 71
- References
- 12
- FWCI
- 10.05
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.